NICE has published draft guidance recommending the use of naftidrofuryl oxalate as a treatment option for people who suffer from intermittent claudication. The work for this appriasal was undertaken by a team of researchers from HEDS - Hazel Squires, Emma Simpson, Yang Meng, Sue Harnan, John Stevens and Ruth Wong. NICE report that “the evidence considered by the Appraisal Committee showed that the others - Cilostazol (Pletal, Otsuka Pharmaceuticals), Pentoxifylline (Trental 400, Sanofi-Aventis) and Inositol nicotinate (Hepoxal, Genus Phamaceuticals) - are not as clinically or cost effective as naftidrofuryl oxalate so they are not recommended as treatment options in the draft guidance”.
The ERG report - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease - is available online and is a classic piece of HTA including a comprehensive search of the literature, a systematic review, a novel network meta-analysis and a de novo cost-effectiveness model.
Further details are available from Hazel Squires.
